PAVMED's Lucid Diagnostics raises $13.625M via Series A Preferred private placement

PAVmed Inc.

Issued 13,625 shares of Series A Convertible Preferred at $1,000/share; gross proceeds $13.625M.
Closing occurred on March 7, 2023; private placement with accredited investors.
Certificate of Designation filed with Delaware establishing Series A Preferred terms.
Further details incorporated by reference to Lucid Diagnostics' Form 8-K filed March 13, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PAVmed Inc. entered into Subscription Agreement with certain accredited investors valued at $13.625 million (effective 2023-03-07).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $13.625 million
Effective: 2023-03-07

Exact text from the filing

On March 7, 2023, Lucid Diagnostics Inc. (the “ Lucid Diagnostics ” or the “ Company ”) entered into subscription agreements (each, a “ Subscription Agreement ”) with certain accredited investors for the sale of 13,625 shares of newly designated Series A Convertible Preferred Stock, par value $0.001 per share (the “ Series A Preferred Stock ”), at a purchase price of $1,000 per share, for aggregate gross proceeds to the Company of $13.625 million, in a private placement (the “ Preferred Offering ”).

View on SEC.gov

Browse all material agreements →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-007473

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.